Free Trial
NYSE:GSK

GSK Q3 2025 Earnings Report

GSK logo
$43.66 -1.85 (-4.07%)
Closing price 10/2/2025 03:59 PM Eastern
Extended Trading
$43.66 0.00 (0.00%)
As of 10/2/2025 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GSK EPS Results

Actual EPS
N/A
Consensus EPS
$1.22
Beat/Miss
N/A
One Year Ago EPS
N/A

GSK Revenue Results

Actual Revenue
N/A
Expected Revenue
$8.21 billion
Beat/Miss
N/A
YoY Revenue Growth
N/A

GSK Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Wednesday, October 29, 2025
Conference Call Time
8:00AM ET

Conference Call Resources

GSK Earnings Headlines

$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.tc pixel
See More GSK Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like GSK? Sign up for Earnings360's daily newsletter to receive timely earnings updates on GSK and other key companies, straight to your email.

About GSK

GlaxoSmithKline (NYSE:GSK (NYSE:GSK)) is a British multinational pharmaceutical company headquartered in London, England. The company focuses on the research, development, manufacturing and marketing of prescription medicines and vaccines. GSK maintains a global presence, supplying health products to markets across North America, Europe, Asia, Latin America and emerging economies.

In its pharmaceuticals segment, GSK develops treatments in areas such as respiratory disease, HIV/infectious disease and oncology. Its portfolio includes respiratory medicines like Breo Ellipta and Anoro Ellipta, as well as HIV therapies such as Tivicay and Triumeq. GSK’s vaccines division produces immunizations against meningitis, shingles and influenza, with well-known brands including Bexsero, Shingrix and Fluarix. The company supports its marketed products with an extensive pipeline of clinical-stage candidates in immunology, oncology and rare diseases.

GSK was formed in 2000 through the merger of Glaxo Wellcome and SmithKline Beecham, creating one of the world’s largest research-based healthcare companies. In July 2022, GSK completed the spin-off of its consumer healthcare business as Haleon, sharpening its strategic focus on pharmaceuticals and vaccines. The company operates research centers in the UK, the United States and other key innovation hubs.

Under the leadership of Chief Executive Officer Emma Walmsley, appointed in 2017, GSK emphasizes collaborations with academic institutions, biotech partners and public-sector organizations. The company continues to invest heavily in R&D, aiming to bring new therapies and preventive vaccines to patients worldwide.

View GSK Profile

More Earnings Resources from MarketBeat